CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody","$":{"href":"/biotech/roche-inks-153-billion-biobucks-deal-simceres-b-cell-targeting-antibody","hreflang":"en"}}]}

Trispecific antibodyPositive
AI Analysis

Summary

Roche is acquiring global rights to Simcere Zaiming's preclinical trispecific antibody targeting B-cell-mediated diseases in a deal valued at $1.53 billion, with $75 million upfront.

Importance:7/10
Sentiment:
0.60
acquisitiononcologyantibodypreclinicalB-cellpartnership
Related Companies

Read the original article

Published by FierceBiotech on September 1, 2026 10:01 AM

Read Original